Influence of antiparkinson drugs and amphetamine on some pharmacological effects of phenothiazine derivatives used as neuroleptics.
D000661:Amphetamine / Q000009:adverse effects; D000818:Animals; D001058:Apomorphine / Q000009:adverse effects; D001362:Avoidance Learning; D001522:Behavior, Animal; D001831:Body Temperature / Q000187:drug effects; D002375:Catalepsy / Q000209:etiology; D002746:Chlorpromazine / Q000494:pharmacology*; D003913:Dextroamphetamine / Q000494:pharmacology*; D004285:Dogs; D006801:Humans; D008409:Mastication; D051379:Mice; D009068:Movement; D010424:Pentobarbital / Q000494:pharmacology; D010546:Perphenazine / Q000494:pharmacology*; D051381:Rats; D012601:Scopolamine / Q000494:pharmacology*; D014268:Trifluoperazine / Q000494:pharmacology*; D014282:Trihexyphenidyl / Q000494:pharmacology*; D014839:Vomiting / Q000209:etiology
D014268:Trifluoperazine; D014282:Trihexyphenidyl; D000661:Amphetamine; D012601:Scopolamine; D010546:Perphenazine; D010424:Pentobarbital; D001058:Apomorphine; D003913:Dextroamphetamine; D002746:Chlorpromazine